International Journal of Hematology and Oncology 2020, Vol 30, Num 2 Page(s): 8-12
The Three Year Follow-up of CML Patients Treated with First-line Generic and First-line Branded Imatinib in Bosnia and Herzegovina

Erna ISLAMAGIC1, Sabira KURTOVIC2, Mirza KOZARIC3, Emina S. HADZIMESIC2, Azra HASIC1, Lejla MEHINOVIC1, Amina KURTOVIC-KOZARIC4

1University of Sarajevo, Faculty of Science, Department of Biochemistry and Physiology, BOSNIA and HERZEGOVINA
2University of Sarajevo Clinical Center, Department of Haematology, BOSNIA and HERZEGOVINA
3University of Sarajevo Clinical Center, Department of Obstetrics and Gynecology, BOSNIA and HERZEGOVINA
4University of Sarajevo Clinical Center, Department of Pathology, Cytology and Human Genetics, Sarajevo, BOSNIA and HERZEGOVINA

Keywords: Generic imatinib, Glivec, Clinical outcomes, CML
Imatinib mesylate, a selective BCR-ABL tyrosine kinase inhibitor, has been well established as the standard of care for chronic myeloid leukaemia patients. In this study, we compared clinical outcomes of patients who received first-line Glivec (Group 1) with patients who received first-line generic imatinib (Group 2) in Bosnia and Herzegovina with three years follow-up of therapy. At 24 months of therapy, the achievement of complete cytogenetic response and major molecular response were comparable between the studied groups (CCyR was 69% vs. 70%, respectively; MMR was 54% vs. 48%, respectively). After comparing the reasons for the switch to nilotinib, we found that treatment failure was higher in patients treated with generic imatinib (30% vs. 8%, respectively) and side effects were similar in both patient groups (22% vs. 19%, respectively). In general, patients on first-line generic imatinib had higher rates of treatment failure compared to patients treated with first-line branded imatinib.